Cargando…

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Mantsounga, Chris Sorel, Morrison, Alan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872768/ https://www.ncbi.nlm.nih.gov/pubmed/31769446 http://dx.doi.org/10.1016/j.jacbts.2019.08.003

Ejemplares similares

The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model
por: Ha, Chae-Myeong, et al.
Publicado: (2019)

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?
por: Mann, Douglas L., et al.
Publicado: (2017)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(−/−) mice
por: Adingupu, Damilola D., et al.
Publicado: (2019)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
por: Anker, Stefan D., et al.
Publicado: (2018)

Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure
por: Packer, Milton
Publicado: (2023)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

Unraveling the Mechanisms by Which Calpain Inhibition Prevents Heart Failure Development
por: Wehrens, Xander H.T.
Publicado: (2018)

More support for Earth’s massive microbiome
por: Lennon, Jay T., et al.
Publicado: (2020)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Publicado: (2022)

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
por: Xu, Yixiang, et al.
Publicado: (2023)

Anticoagulation in patients with mechanical heart valves: follow the guidelines!
por: Verheugt, Freek W.A.
Publicado: (2015)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

RAS inhibition and COVID-19: more questions than answers?
por: Kerneis, Mathieu, et al.
Publicado: (2021)

Short-term mechanical support and pharmacotherapy, a new strategy in cardiogenic shock?
por: Tseng, C. C. S., et al.
Publicado: (2014)

The “discordant doppelganger dilemma”: SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?
por: Murray, Scott W., et al.
Publicado: (2021)

More than honour, humanitarian health-care workers need life-saving protection
por: Langlois, Etienne V, et al.
Publicado: (2021)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Sharing GWAS summary statistics results in more citations
por: Reales, Guillermo, et al.
Publicado: (2023)

Is Protein Kinase C Inhibition the Tip of the Iceberg in New Therapeutics for Acutely Decompensated Heart Failure?
por: Pimental, David R., et al.
Publicado: (2017)

Commentary on the association of blood group antigens with post-implant thrombosis of mechanical heart valves
por: Pourafkari, Leili, et al.
Publicado: (2016)

Cardio-Oncology: Time to Get More Mechanistic
por: Moslehi, Javid, et al.
Publicado: (2017)

More on the invisibility of chronic kidney disease… and counting
por: Carriazo, Sol, et al.
Publicado: (2021)

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
por: Young, Katherine G., et al.
Publicado: (2023)

Refueling the Failing Heart: A Case for Sodium-Glucose Cotransporter 2 Inhibition in Cardiac Energy Homeostasis
por: Crawford, Peter A.
Publicado: (2018)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e9hg19uck72a1ne1cakp1aoga7